Pharmacologic treatment of autism

Journal of Child Neurology

Volumn 19, Issue 3, 2004, Pages 155-164

  Palermo, Mark T ^a   Curatolo, Paolo ^b  

^a Associazione Anni Verdi   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMANTADINE; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BUSPIRONE; CARBAMAZEPINE; CLOMIPRAMINE; CLOZAPINE; DESIPRAMINE; FENFLURAMINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LAMOTRIGINE; METHYLPHENIDATE; NALTREXONE; NEUROLEPTIC AGENT; OLANZAPINE; OPIATE AGONIST; PAROXETINE; PIMOZIDE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTRALINE; VALPROIC ACID;

AGRANULOCYTOSIS; AUTISM; CHRONIC DISEASE; DEVELOPMENTAL DISORDER; DIAGNOSTIC TEST; DRUG BLOOD LEVEL; DYSTONIA; ENTEROPATHY; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; HUMAN; IRRITABILITY; LANGUAGE DISABILITY; MEDICAL CARE; MENTAL PATIENT; MOLECULAR GENETICS; MOTOR DYSFUNCTION; PATHOGENESIS; PATIENT CODING; PHARMACOGENETICS; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; TACHYCARDIA; WEIGHT GAIN;

ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; BRAIN; CHILD; CHROMOSOME ABERRATIONS; CHROMOSOME MAPPING; CLINICAL TRIALS; DOPAMINE AGENTS; HUMANS; PHARMACOGENETICS; PSYCHOTROPIC DRUGS; SEROTONIN UPTAKE INHIBITORS;

EID: 2342417739     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (168)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC, American Psychiatric Press, 1994.
2. Rapin I: The autistic-spectrum disorders. N Engl J Med 2002; 347:302-303.
3. Ehlers S, Gillberg C: The epidemiology of Asperger syndrome. A total population study. J Child Psychol Psychiatry 1993; 34:1327-1350.
4. Bertrand J, Mars A, Boyle C, et al: Prevalence of autism in a United States popluation: The Brick Township, New Jersey, investigation. Pediatrics 2001;108:1155-1161.
5. Kadesjo B, Gillberg C, Hagberg B: Brief report: Autism and Asperger syndrome in seven-year-old children: A total poplation study. J Autism Dev Disord 1999;29:327-331.
6. Lotter, V: Epidemiology of autistic conditions in young children, I. Prevalence. Soc Psychiatry 1974;1:124-137.
7. Baird G, Charman T, Baron-Cohen S et al: A screening instrument for autism at 18 months of age: A 6-year follow-up study. J Child Psychol Psychiatry 2000;39:694-702.
8. Bryson SE: Epidemiology of autism: Overview and issues outstanding, in Cohen DJ, Volkmar FR (eds): Handbook of Autism and Pervasive Developmental Disorders, 2nd ed. New York, Wiley, 1997, 41-46.
9. Bailey A, Le Couteur A, Gottesman I, et al: Autism as a strongly genetic disorder: Evidence from a British twin study. Psychol Med 1995;25:63-77.
10. Rutter M, Silberg J, O'Connor T, Simonoff E: Genetics and child psychiatry: II Empirical research findings. J Child Psychol Psychiatry 1999;40:19-55.
11. Kemper TL, Bauman M: Neuropathology of infantile autism. J Neuropathol Exp Neurol 1998;57:645-652.
12. Ritvo ER, Freeman BJ, Scheibel AB, et al: Lower Purkinje cell counts in the cerebella of four autistic subjects: initial findings of the UCLA-NSAC Autopsy Research Report. Am J Psychiatry 1986;143:862-866.
13. Courchesne E: Brainstem, cerebellar and limbic neuroanatomical abnormalities in autism. Curr Opin Neurobiol 1997;7:269-278.
14. Salmond CH, de Haan M, Friston KJ, et al: Investigating individual differences in brain abnormalities in autism. Philos Trans R Soc Lond B Biol Sci 2003;358:405-413.
15. Tsatsanis KD, Rourke BP, Klin A, et al: Reduced thalamic volume in high-functioning individuals with autism. Biol Psychiatry 2003;53:121-129.
16. Herbert MR, Harris GJ, Adrien KT, et al: Abnormal asymmetry in language association cortex in autism. Ann Neurol 2002;52: 588-596.
17. Risch N, Spiker D, Lotspeich L, et al: A genomic screen of autism: Evidence for a multilocus etiology. Am J Hum Genet 1999; 65:493-507.
18. Auranen M, Nieminen T, Majuri S, et al: Analysis of autism susceptibility gene loci on chromosomes 1p, 4p, 6q, 7q, 13q, 15q, 16p, 17q, 19q and 22q in Finnish multiplex families. Mol Psychiatry 2000;5:320-322.
19. Philippe A, Martinez M, Guilloud-Bataille M, et al: Genome-wide scan for autism susceptibility genes. Paris Autism Research International Sibpair Study. Hum Mol Genet 1999;8:805-812.
20. Barrett S, Beck JC, Bernier R, et al: An autosomal genomic screen for autism. Collaborative linkage study of autism. Am J Med Genet 1999;88:609-615.
21. Maestrini E, Paul A, Monaco AP, Bailey A. Identifying autism susceptibility genes. Neuron 2000;28:19-24.
22. Lucarelli P, Palminiello S, Saccucci P, et al: Association study of autistic disorder and chromosome 16p. Am J Hum Genet 2003; 119A(2):242-246.
23. Cook EH Jr, Courchesne RY, Cox NJ, et al: Linkage-disequilibrium mapping of autistic disorder, with 15q11-13 markers. Am J Hum Genet 1998;62:1077-1083.
24. Gurrieri F, Battaglia A, Torrisi L, et al: Pervasive developmental disorder and epilepsy due to maternally derived duplication of 15q11-q13. Neurology 1999;52:1694-1697.
25. Lord C, Cook EH, Leventhal BL, Amaral DG: Autism spectrum disorders. Neuron 2000;28:355-363.
26. Smalley SL, Kustanovich V, Minassian SL, et al: Genetic linkage of attention-deficit/hyperactivity disorder on chromosome 16p13, in a region implicated in autism. Am J Hum Genet 2002;71:959-963.
27. International Molecular Genetic Study of Autism Consortium: A full genome screen for autism with evidence for linkage to a region on chromosome 7q. Hum Mol Genet 1998;7:571-578.
28. Ashley-Koch A, Wolpert CM, Menold MM, et al: Genetic studies of autistic disorder and chromosome 7. Genomics 1999;61:227-236.
29. Veenstra-VanderWeele J, Kim SJ, Lord C, et al: Transmission disequilibrium studies of the serotonin 5-HT2A receptor gene (HTR2A) in autism. Am J Med Genet 2002;114:277-283.
30. Zhang H, Liu X, Zhang C, et al: Reelin gene alleles and susceptibility to autism spectrum disorders. Mol Psychiatry 2002; 7:1012-1017.
31. Krebs MO, Betancur C, Leroy S, et al: Absence of association between a polymorphic GGC repeat in the 5′ untranslated region of the reelin gene and autism. Mol Psychiatry 2002;7:801-804.
32. Persico AM, D'Agruma L, Maiorano N, et al: Reelin gene alleles and haplotypes as a factor predisposing to autistic disorder. Mol Psychiatry 2001;6:150-159.
33. Persico AM, Pascucci T, Puglisi-Allegra S, et al: Serotonin transporter gene promoter variants do not explain the hyperserotoninemia in autistic children. Mol Psychiatry 2002;7:795-800.
34. Bottini N, De Luca D, Saccucci P, et al: Autism: Evidence of association with adenosine deaminase genetic polymorphism. Neurogenetics 2001;3:111-113.
35. Curatolo P, Verdecchia M, Bombardieri R: Tuberous sclerosis complex: A review of neurological aspects. Eur J Paediatr Neurol 2002;6:15-23.
36. Smalley SL: Autism and tuberous sclerosis. J Autism Dev Disord 1998;28:407-414.
37. Asano E, Chugani DC, Muzik O, et al: Autism in tuberous sclerosis complex is related to both cortical and subcortical dysfunction. Neurology 2001;57:1269-1277.
38. Feinstein C, Reiss AL: Autism: The point of view from fragile X studies. J Autism Dev Disord 1998;28:393-405.
39. Skuse DH: Imprinting, the X-chromosome, and the male brain: Explaining sex differences in the liability to autism. Pediatr Res 2000;47:9-16.
40. Pelios LV, Lund SK: A selective overview of issues on classification, causation, and early intensive behavioral intervention for autism. Behav Modif 2001;25:678-697.
41. Volkmar F, Cook EH Jr, Pomeroy J, et al: Practice parameters for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders. American Academy of Child and Adolescent Psychiatry Working Group on Quality Issues. J Am Acad Child Adolesc Psychiatry 1999;38(12 Suppl):32S-54S.
42. Andres C: Molecular genetics and animal models in autistic disorder. Brain Res Bull 2002;57:109-119.
43. McDougle CJ, Kresch LE, Goodman WK, et al: A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder. Am J Psychiatry 1995;152:772-777.
44. Klin A, Jones W, Schultz R, et al: Defining and quantifying the social phenotype in autism. Am J Psychiatry 2002;159:895-908.
45. Militerni R, Bravaccio C, Falco C, et al: Repetitive behaviors in autistic disorder. Eur Child Adolesc Psychiatry 2002;11:210-218.
46. Baron-Cohen S: Do autistic children have obsessions and compulsions? Br J Clin Psychol 1989;28(Pt 3):193-200.
47. Dawson JE, Matson JL, Cherry KE: An analysis of maladaptive behaviors in persons with autism, PDD-NOS, and mental retardation. Res Dev Disabil 1998;19:439-448.
48. McDougle CJ, Scahill L, McCracken JT, et al: Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone. Child Adolesc Psychiatr Clin N Am 2000;9:201-224.
49. Chugani DC, Muzik O, Behen M, et al: Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann Neurol 1999;45:287-295.
50. Anderson GM, Cook EH: Pharmacogenetics. Promise and potential in child and adolescent psychiatry. Child Adolesc Psychiatr Clin N Am 2000;9:23-42.
51. Cook EH Jr, Courchesne R, Lord C, et al: Evidence of linkage between the serotonin transporter and autistic disorder. Mol Psychiatry 1997;2:247-250.
52. Klauck SM, Poustka F, Benner A, et al: Serotonin transporter (5-HTT) gene variants associated with autism? Hum Mol Genet 1997;6:2233-2238.
53. Persico AM, Militerni R, Bravaccio C, et al: Lack of association between serotonin transporter gene promoter variants and autistic disorder in two ethnically distinct samples. Am J Med Genet 2000;96:123-127.
54. Lesch KP, Mossner R: Genetically driven variation in serotonin uptake: Is there a link to affective spectrum, neurodevelopmental, and neurodegenerative disorders? Biol Psychiatry 1998;44:179-192.
55. Persico AM, Pascucci T, Puglisi-Allegra S, et al: Serotonin transporter gene promoter variants do not explain the hyperserotoninemia in autistic children. Mol Psychiatry 2002;7:795-800.
56. Ritvo ER, Freeman BJ, Yuwiler A, et al: Fenfluramine treatment of autism: UCLA collaborative study of 81 patients at nine medical centers. Psychopharmacol Bull 1986;22:133-140.
57. Campbell M, Adams P, Small AM, et al: Efficacy and safety of fenfluramine in autistic children. J Am Acad Child Adolesc Psychiatry 1988;27:434-439.
58. Ekman G, Miranda-Linne F, Gillberg C, et al: Fenfluramine treatment of twenty children with autism. J Autism Dev Disord 1989;19:511-532.
59. Schuster CR, Lewis M, Seiden LS: Fenfluramine: Neurotoxicity. Psychopharmacol Bull 1986;22:148-151.
60. Connolly HM, Crary JL, McGoon MD, et al: Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-588.
61. DeLong GR, Teague LA, McSwain Kamran M: Effects of fluoxetine treatment in young children with idiopathic autism. Dev Med Child Neurol 1998;40:551-562.
62. McDougle CJ, Naylor ST, Cohen DJ, et al: A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996;53:1001-1008.
63. Gordon CT, Rapoport JL, Hamburger SD, et al: Differential response of seven subjects with autistic disorder to clomipramine and desipramine. Am J Psychiatry 1992;149:363-366.
64. Gordon CT, State RC, Nelson JE, et al: A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 1993;50:441-447.
65. Olsson I, Steffenburg S, Gillberg C: Epilepsy in autism and autisticlike conditions. A population-based study. Arch Neurol 1988;45:666-668.
66. Remington G, Sloman L, Konstantareas M, et al: Clomipramine versus haloperidol in the treatment of autistic disorder: A double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol 2001;21:440-444.
67. DeVane CL, Sallee FR: Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: A review of published experience. J Clin Psychiatry 1996;57:55-66.
68. Go FS, Malley EE, Birmaher B, Rosenberg DR: Manic behaviors associated with fluoxetine in three 12- to 18-year-olds with obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 1998;8:73-80.
69. Chugani DC, Muzik O, Behen M, et al: Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann Neurol 1999;45:287-295.
70. McBride PA, Anderson GM, Hertzig ME, et al: Effects of diagnosis, race, and puberty on platelet serotonin levels in autism and mental retardation. J Am Acad Child Adolesc Psychiatry 1998;37:767-776.
71. Vitiello B: Pediatric psychopharmacology and the interaction between drugs and the developing brain. Can J Psychiatry 1998;43:582-584.
72. Gillberg C, Svennerholm L, Hamilton-Hellberg C: Childhood psychosis and monoamine metabolites in spinal fluid. J Autism Dev Disord 1983;13:383-396.
73. Anderson GM, Hoshino Y: Neurochemical studies of autism, in Cohen DJ, Volkmar FR (eds): Handbook of Autism and Developmental Disorders, 2nd ed. New York, John Wiley & Sons, 1997,325-343.
74. Anderson LT, Campbell M, Adams P, et al: The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 1989;19:227-239.
75. Nieoullon A: Dopamine and the regulation of cognition and attention. Prog Neurobiol 2002;67:53-83.
76. Sulzer D, Joyce MP, Lin L, et al: Dopamine neurons make glutamatergic synapses in vitro. J Neurosci 1998;18:4588-4602.
77. Purcell AE, Jeon OH, Zimmerman AW, et al: Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology 2001;57:1618-1628.
78. King BH, Wright DM, Handen BL, et al: Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry 2001;40:658-665.
79. Cohen IL, Campbell M, Posner D, et al: Behavioral effects of haloperidol in young autistic children. An objective analysis using a within-subjects reversal design. J Am Acad Child Psychiatry 1980;19:665-677.
80. Campbell M, Anderson LT, Meier M, et al: A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry 1978;17:640-655.
81. Anderson LT, Campbell M, Grega DM, et al: Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms. Am J Psychiatry 1984;141:1195-1202.
82. Anderson LT, Campbell M, Adams P, et al: The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 1989;19:227-239.
83. Perry R, Campbell M, Adams P, et al: Long-term efficacy of haloperidol in autistic children: Continuous versus discontinuous drug administration. J Am Acad Child Adolesc Psychiatry 1989; 28:87-92.
84. Campbell M, Armenteros JL, Malone RP, et al: Neuroleptic-related dyskinesias in autistic children: A prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 1997;36:835-843.
85. Naruse H, Nagahata M, Nakane Y, et al: A multi-center double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavioral disorders, using crossover design. Acta Paedopsychiatr 1982;48:173-184.
86. Fulop G, Phillips RA, Shapiro AK, et al: ECG changes during haloperidol and pimozide treatment of Tourette's disorder. Am J Psychiatry 1987;144:673-675.
87. Goodnick PJ, Jerry J, Parra F: Psychotropic drugs and the ECG: Focus on the QTc interval. Exp Opin Pharmacother 2002; 3:479-498.
88. Desta Z, Kerbusch T, Flockhart DA: Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther 1999;65:10-20.
89. Davis JM, Janicak PG: Efficacy and safety of the new antipsychotics. Lancet 1994;343:476-477.
90. Potenza MN, Holmes JP, Kanes SJ, McDougle CJ: Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: An open-label pilot study. J Clin Psychopharmacol 1999;19:37-44.
91. Leysen JE, Gommeren W, Eens A, et al: Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988;247:661-670.
92. Chouinard G, Arnott W: Clinical review of risperidone. Can J Psychiatry 1993;38(Suppl 3):S89-S95.
93. Purdon SE, Lit W, Labelle A, Jones BD: Risperidone in the treatment of pervasive developmental disorder. Can J Psychiatry 1994;39:400-405.
94. McDougle CJ, Holmes JP, Carlson DC, et al: A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 1998;55:633-634.
95. Perry R, Pataki C, Munoz-Silva DM, et al: Risperidone in children and adolescents with pervasive developmental disorder: Pilot trial and follow-up. J Child Adolesc Psychopharmacol 1997; 7:167-179.
96. McDougle CJ, Holmes JP, Bronson MR, et al: Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective open-label study. J Am Acad Child Adolesc Psychiatry 1997;36:685-693.
97. Nicolson R, Awad G, Sloman L: An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry 1998;37:372-376.
98. Meltzer HY, McGurk SR: The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999;25:233-235.
99. Krebs S, Dormann H, Muth-Selbach U, et al: Risperidone-induced cholestatic hepatitis. Eur J Gastroenterol Hepatol 2001;13:67-69.
100. Szigethy E, Wiznitzer M, Branicky LA, et al: Risperidone-induced hepatotoxicity in children and adolescents? A chart review study. J Child Adolesc Psychopharmacol 1999;9:93-98.
101. Mandoki MW: Risperidone treatment of children and adolescents: Increased risk of extrapyramidal side-effects? J Child Adolesc Psychopharmacol 1995;5:49-67.
102. Zuddas A, Ledda MG, Fratta A, et al: Clinical effects of clozapine on autistic disorder. Am J Psychiatry 1996;153:738.
103. Horrigan JP, Barnhill LJ, Courvoisie HE: Olanzapine in PDD. J Am Acad Child Adolesc Psychiatry 1997;36:1166-1167.
104. Martin A, Koenig K, Scahill L, Bregman J: Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 1999;9:99-107.
105. Weinberg WA, Brumback RA: Primary disorder of vigilance: A novel explanation of inattentiveness, daydreaming, boredom, restlessness, and sleepiness. J Pediatr 1990;116:720-725.
106. Weinberg WA, Schraufnagel CD, Harper CR, Brumback RA: Algorithms for the treatment of affective illness, primary disorder of vigilance, and task-dependent attention disorders (learning disabilities) in children and adolescents. J Child Neurol 1996;11:220-227.
107. Smalley SL, McCracken J, Tanguay P: Autism, affective disorders, and social phobia. Am J Med Genet 1995;60:19-26.
108. Kutcher S: Practical clinical issues regarding child and adolescent psychopharmacology. Child Adolesc Psychiatr Clin N Am 2000; 9:245-260.
109. Lainhart JE, Folstein SE: Affective disorders in people with autism: A review of published cases. J Autism Dev Disord 1994;24:587-601.
110. Piven J, Gayle J, Chase GA, et al: A family history study of neuropsychiatric disorders in the adult siblings of autistic individuals. J Am Acad Child Adolesc Psychiatry 1990;29:177-183.
111. Costello EJ, Pine DS, Hammen C, et al: Development and natural history of mood disorders. Biol Psychiatry 2002;52:529-542.
112. Weckerly J: Pediatric bipolar mood disorder. J Dev Behav Pediatr 2002;23:42-56.
113. Schraufnagel CD, Brumback RA, Harper CR, Weinberg WA: Affective illness in children and adolescents: Patterns of presentation in relation to pubertal maturation and family history. J Child Neurol 2001;16:553-561.
114. Marston GM, Perry DW, Roy A: Manifestations of depression in people with intellectual disability. J Intellect Disabil Res 1997;41:476-480.
115. Davis JP, Judd FK, Herrman H: Depression in adults with intellectual disability. Part 2: A pilot study. Aust N Z J Psychiatry 1997;31:243-251.
116. Geller B, Luby J: Child and adolescent bipolar disorder: A review of the past 10 years. J Am Acad Child Adolesc Psychiatry 1997; 36:1168-1176.
117. Komoto J, Usui S, Hirata J: Infantile autism and affective disorder. J Autism Dev Disord 1984;14:81-84.
118. Ghaziuddin M, Ghaziuddin N, Greden J: Depression in persons with autism: Implications for research and clinical care. J Autism Dev Disord 2002;32:299-306.
119. Vitriol C, Farber B: Stimulant medication in certain childhood disorders. Am J Psychiatry 1981;138:1517-1518.
120. Quintana H, Birmaher B, Stedge D, et al: Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord 1995;25:283-294.
121. Geller B, Guttmacher LB, Bleeg M: Coexistence of childhood onset pervasive developmental disorder and attention deficit disorder with hyperactivity. Am J Psychiatry 1981;138:388-389.
122. Schmidt K: The effect of stimulant medication in childhood-onset pervasive developmental disorder - A case report. J Dev Behav Pediatr 1982;3:244-246.
123. Volkmar FR, Hoder EL, Cohen DJ: Inappropriate uses of stimulant medications. Clin Pediatr (Phila) 1985;24:127-130.
124. Aman MG, Langworthy KS: Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders. J Autism Dev Disord 2000;30:451-459.
125. Handen BL, Johnson CR, Lubetsky M: Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 2000;30:245-255.
126. Spencer T, Wilens T, Biederman J: Psychotropic medication for children and adolescents. Child Adolesc Clin N Am 1995;4:1, 97-121.
127. Courchesne E, Townsend J, Akshoomoff NA, et al: Impairment in shifting attention in autistic and cerebellar patients. Behav Neurosci 1994;108:848-865.
128. Courchesne E, Press GA, Yeung-Courchesne R: Parietal lobe abnormalities detected with MR in patients with infantile autism. AJR Am J Roentgenol 1993;160:387-393.
129. Brumback RA: Is depression a neurologic disease? Neurol Clin 1993;11:79-104.
130. Brumback RA, Weinberg WA: Pediatric behavioral neurology: An update on the neurologic aspects of depression, hyperactivity, and learning disabilities. Neurol Clin 1990;8:677-703.
131. Ghaziuddin M, Weidmer-Mikhail E, Ghaziuddin N: Comorbidity of Asperger syndrome: A preliminary report. J Intellect Disabil Res 1998;42(Pt 4):279-283.
132. van der Geest JN, Kemner C, Camfferman G, et al: Eye movements, visual attention, and autism: A saccadic reaction time study using the gap and overlap paradigm. Biol Psychiatry 2001;50:614-619.
133. Minshew NJ, Luna B, Sweeney JA: Oculomotor evidence for neocortical systems but not cerebellar dysfunction in autism. Neurology 1999;52:917-922.
134. Pierce K, Courchesne E: Evidence for a cerebellar role in reduced exploration and stereotyped behavior in autism. Biol Psychiatry 2001;49:655-664.
135. Buitelaar JK, van der Gaag RJ, van der Hoeven J: Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: Results of an open-label study. J Clin Psychiatry 1998;59:56-59.
136. Fankhauser MP, Karumanchi VC, German ML, et al: A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 1992;53:77-82.
137. Jaselskis CA, Cook EH Jr, Fletcher KE, Leventhal BL: Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 1992;12:322-327.
138. Campbell M, Anderson LT, Small AM, et al: Naltrexone in autistic children: behavioral symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry 1993;32(6):1283-1291.
139. Willemsen-Swinkels SH, Buitelaar JK, Nijhof GJ, van Engeland H: Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Double-blind placebo-controlled studies. Arch Gen Psychiatry 1995;52:766-773.
140. Willemsen-Swinkels SH, Buitelaar JK, van Engeland H: The effects of chronic naltrexone treatment in young autistic children: A double-blind placebo-controlled crossover study. Biol Psychiatry 1996;39:1023-1031.
141. Di Martino A, Tuchman RF: Antiepileptic drugs: Affective use in autism spectrum disorders. Pediatr Neurol 2001;25:199-207.
142. Muzina DJ, El-Sayegh S, Calabrese JR: Antiepileptic drugs in psychiatry - focus on randomized controlled trial. Epilepsy Res 2002;50:195-202.
143. Tuchman RF, Rapin I: Regression in pervasive developmental disorders: Seizures and epileptiform electroencephalogram correlates. Pediatrics 1997;99:560-566.
144. Tuchman RF: Acquired epileptiform aphasia. Semin Pediatr Neurol 1997;4:93-101.
145. Shinnar S, Rapin I, Arnold S, et al: Language regression in childhood. Pediatr Neurol 2001;24:183-189.
146. Nass R, Devinsky O: Autistic regression with rolandic spikes. Neuropsychiatry Neuropsychol Behav Neurol 1999;12:193-197.
147. Pitkanen A: Drug-mediated neuroprotection and antiepileptogenesis: Animal data. Neurology 2002;59(9 Suppl 5):S27-S33.
148. Cole AJ, Dichter M: Neuroprotection and antiepileptogenesis: Overview, definitions, and context. Neurology 2002;59(9 Suppl. 5):S1-S2.
149. Dailey JW, Reith ME, Steidley KR, et al: Carbamazepine-induced release of serotonin from rat hippocampus in vitro. Epilepsia 1998;39:1054-1063.
150. Baf MH, Subhash MN, Lakshmana KM, Rao BS: Alterations in monoamine levels in discrete regions of rat brain after chronic administration of carbamazepine. Neurochem Res 1994;19: 1139-1143.
151. Baf MH, Subhash MN, Lakshmana KM, Rao BS: Sodium valproate induced alterations in monoamine levels in different regions of the rat brain. Neurochem Int 1994;24:67-72.
152. Casanova MF, Buxhoeveden DP, Switala AE, Roy E: Minicolumnar pathology in autism. Neurology 2002;58:428-432.
153. Casanova MF, Buxhoeveden DP, Switala AE, Roy E: Neuronal density and architecture (gray level index) in the brains of autistic patients. J Child Neurol 2002;17:515-521.
154. Carlsson ML: Hypothesis: Is infantile autism a hypoglutamatergic disorder? Relevance of glutamate-serotonin interactions for pharmacotherapy. J Neural Transm 1998;106:525-535.
155. Blue ME, Naidu S, Johnston MV: Altered development of glutamate and GABA receptors in the basal ganglia of girls with Rett syndrome. Exp Neurol 1999;156:345-352.
156. Belsito KM, Law PA, Kirk KS, et al: Lamotrigine therapy for autistic disorder: A randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 2001;31:175-181.
157. Bauman ML, Kemper TL: Neuroanatomic observations of the brain in autism, in Bauman ML, Kemper TL (eds): The Neurobiology of Autism. Baltimore and London, The Johns Hopkins University Press, 1994, 119-145.
158. Perry EK, Lee ML, Martin-Ruiz CM, et al: Cholinergic activity in autism: Abnormalities in the cerebral cortex and basal forebrain. Am J Psychiatry 2001;158:1058-1066.
159. Chez MG, Nowinski CV, Buchanan CP, Jones C: Donepezil (Aricept) use in children with autistic spectrum disorders. Am Neurol 2000;48:541.
160. Hardan AY, Handen BL: A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 2002;12:3, 237-241.
161. Minshew N, Goldstein G, Siegel D: Neuropsychological functioning in autism: Profile of a complex information processing disorder. J Int Neuropsychol Soc 1997;3:303-316.
162. Ciardo F, Salerno C, Curatolo P: Neurologic aspects of adenylosuccinate lysase deficiency. J Child Neurol 2001;16:301-308.
163. Van den Berghe G, Jaeken J: Adenylosuccinase deficiency. Adv Exp Med Biol 1986;195(Pt A):27-33.
164. Salerno C, Crifò C, Curatolo P, Ciardo F: Effect of uridine administration to a patient with adenylosuccinate lyase deficiency. Adv Exp Med Biol 2000;486:75-78.
165. Carlton PL, Manowitz P: Dopamine and schizophrenia: An analysis of the theory. Neurosci Biobehav Rev 1984;8:137-151.
166. Gustafsson L: Inadequate cortical feature maps: A neural circuit theory of autism. Biol Psychiatry 1997;42:1138-1147.
167. Vitiello B: Psychopharmacology for young children: Clinical needs and research opportunities. Pediatrics 2001;108:983-989.
168. Arnold LE, Aman MG, Martin A, et al: Assessment in multisite randomized clinical trials of patients with autistic disorder: The Autism RUPP Network. Research Units on Pediatric Psychopharmacology. J Autism Dev Disord 2000;30:99-111.